^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CEACAM6 (CEA Cell Adhesion Molecule 6)

    i
    Other names: CEACAM6, CEA Cell Adhesion Molecule 6, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen), Carcinoembryonic Antigen Related Cell Adhesion Molecule 6, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6, Normal Cross-Reacting Antigen, CD66c, NCA, Non-Specific Crossreacting Antigen, Cluster Of Differentiation 66c, CD66c Antigen, CEAL
    3d
    CEACAM6 regulates glycolytic metabolism in bladder cancer cell by controlling ENO1 stability. (PubMed, Eur J Med Res)
    Our study demonstrated that CEACAM6 regulates glycolysis via the ENO1-AKT/mTOR axis. These results offer new evidence about previously unexplored molecular mechanisms driving BCa progression.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6) • ENO1 (Enolase 1)
    10d
    Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer. (PubMed, Clin Cancer Res)
    GSK-3b blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor suppressive immune microenvironment.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FN1 (Fibronectin 1) • TGFB1 (Transforming Growth Factor Beta 1) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    5-fluorouracil • irinotecan • leucovorin calcium • elraglusib (9-ING-41)
    16d
    Revealing Causal Protein Biomarkers and Potential Therapeutic Targets for Histologic-Specific Lung Cancer. (PubMed, J Cell Mol Med)
    Tier 3 proteins, supported by logistic regression and MR only, included CD5L, GNPDA, ACAN, C7, DMP1, HEPH, CEACAM6, COX6B1, CPXM2 and IL12RB2. Druggability evaluation suggests that existing drugs targeting ITGB2, GP1BA, ACADSB and COX6B1 could potentially be repurposed for the treatment of specific lung cancer subtypes.
    Journal
    |
    CEACAM6 (CEA Cell Adhesion Molecule 6) • ITGB2 (Integrin Subunit Beta 2) • ACAN (Aggrecan) • AGRN (Agrin) • ACADSB (Acyl-CoA Dehydrogenase Short/Branched Chain)
    2ms
    Production of monoclonal antibodies against carcinoembryonic antigen-related cell adhesion molecule 6 and detection of their binding affinities. (PubMed, Tzu Chi Med J)
    In addition, CEAS5, unlike CEAS1-S4, could bind to both CEACAM5 and CEACAM6, indicating its bivalent nature. These findings highlight the strong antigen-binding capabilities of CEAS1-S5, warranting further investigation.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    2ms
    Clinical and Genetic Profiling of Fibromyalgia-Associated Dry Eye: A Multifactorial Approach. (PubMed, Ocul Surf)
    Genetic polymorphisms and immune dysregulation contribute to FM-DED pathophysiology, supporting the need for differentiated diagnosis and targeted therapies.
    Journal
    |
    MUC1 (Mucin 1) • MTHFR (Methylenetetrahydrofolate Reductase) • CEACAM6 (CEA Cell Adhesion Molecule 6) • PSMB8 (Proteasome 20S Subunit Beta 8) • COMT (Catechol-O-Methyltransferase)
    2ms
    Pathogenesis of adherent-invasive Escherichia coli LF82 in human colonic epithelium is characterized by adhesive biofilms, mucus penetration, and contact-dependent cytotoxicity. (PubMed, Gut Microbes)
    However, bacteria adhered preferentially to the mucus layer and penetrated to the epithelial surface. Our results suggest that LF82 pathogenesis in the human colon is characterized by the formation of adherent biofilms, mucus penetration, and contact-dependent cytotoxicity, which likely contributes to epithelial leakage and inflammation in CD.
    Journal
    |
    CEACAM6 (CEA Cell Adhesion Molecule 6)
    2ms
    Strand-specific functions of miR-301a-3p and -5p drive opposing roles in pancreatic cancer via ferroptosis and pyroptosis. (PubMed, Cell Biol Toxicol)
    By highlighting the risks of indiscriminate miRNA targeting, our work supports the development of strand-specific diagnostic and therapeutic strategies in PDAC. This study advances the concept of chain-level regulation as a foundation for precision oncology.
    Journal
    |
    TNFRSF1A (TNF Receptor Superfamily Member 1A) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • CEACAM6 (CEA Cell Adhesion Molecule 6) • CA 19-9 (Cancer antigen 19-9)
    2ms
    Molecular profiling and bioinformatics validation of CEACAM6, HOXA-AS3 and miR29a in colorectal cancer. (PubMed, Sci Rep)
    Integrating molecular profiling with bioinformatics validation provides a robust approach to uncover clinically relevant targets in CRC. The correlation between serum and tumor tissue miR-29a expression highlights its potential utility in liquid biopsy approaches for CRC.
    Journal
    |
    IL6 (Interleukin 6) • CEACAM6 (CEA Cell Adhesion Molecule 6) • MIR29A (MicroRNA 29a)
    2ms
    Multicenter validation of CEACAM6 and FOXP3 as robust prognostic biomarkers in colon cancer: Combined immunohistochemical and transcriptomic analysis. (PubMed, Mol Clin Oncol)
    These findings support their potential integration into clinical risk stratification and the development of targeted immunotherapies. Further mechanistic and prospective studies are warranted to explore their therapeutic applications.
    Clinical • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CEACAM6 (CEA Cell Adhesion Molecule 6) • FOXP3 (Forkhead Box P3)
    2ms
    Exploring the interactions of integrins and CEACAM6 (Review). (PubMed, Exp Ther Med)
    In conclusion, the interaction between CEACAM6 and integrins can influence PDAC progression, desmoplasia and treatment resistance. Targeting this adhesion signaling axis presents a promising strategy to improve diagnostic precision and develop more effective personalized therapies for PDAC.
    Review • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    2ms
    Deciphering tumor-intrinsic and immune characteristics in resectable non-small cell lung cancer treated with neoadjuvant pembrolizumab and chemotherapy. (PubMed, J Transl Med)
    Our study identified molecular biomarkers for pathological and survival outcomes, which may inform optimal treatment decision-making, guide postoperative therapy, and improve survival outcomes for stage II-III patients with resectable NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • B2M (Beta-2-microglobulin) • HMGB1 (High Mobility Group Box 1) • HLA-E (Major Histocompatibility Complex, Class I, E) • ICOSLG (Inducible T Cell Costimulator Ligand) • CEACAM6 (CEA Cell Adhesion Molecule 6) • BTN3A1 (Butyrophilin Subfamily 3 Member A1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Keytruda (pembrolizumab)
    3ms
    Proteomic landscape of colorectal cancer liver metastasis. (PubMed, Transl Oncol)
    These findings provide new insights into the molecular complexities underpinning colorectal cancer liver metastasis. Our identification of CEACAM6 as a differential marker highlights its potential as a diagnosis marker and therapeutic target, offering new avenues for the treatment of metastatic CRC.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CEACAM6 (CEA Cell Adhesion Molecule 6)